Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Synageva BioPharma Corp. (GEVA - Snapshot Report) announced the pricing of its underwritten public offering of its common stock. The company is looking to issue 2.75 million shares at $56.63 per share.

Underwriters have been granted an option to purchase an additional 412,500 shares of Synegeva’s common stock, with a 30-day window to do so.

We believe that Synageva, a company focused on the development and commercialization of therapeutics products for treating patients suffering from rare life-threatening diseases, will most likely use the funds for the development of its pipeline. 

The company has two lead pipeline candidates, sebelipase alfa and SBC-103. Sebelipase alfa and SBC-103 are enzyme replacement therapies being evaluated for the treatment of lysosomal storage diseases (LSD).

Synageva is developing sebelipase alfa for the treatment of early onset of lysosomal acid lipase deficiency (LAL deficiency), also known as Wolman disease. The candidate is currently in a randomized, double-blind, placebo-controlled phase III study, ARISE. The company expects to complete patient enrollment in this study in 2014.

In May 2013, Synageva received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for sebelipase alfa.

The company’s other lead candidate, SBC-103, is being evaluated for mucopolysaccharidosis IIIB (MPS IIIB), also known as Sanfilippo B syndrome. The company intends to start studies on SBC-103 during the first half of 2014.

Synageva carries a Zacks Rank #3 (Hold). Companies that currently look well-positioned include Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy), and Jazz Pharmaceuticals (JAZZ - Analyst Report) and Sarepta Therapeutics, Inc. (SRPT - Snapshot Report) with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%